Core Viewpoint - Baxter International Inc. is facing a class action lawsuit due to allegations of misleading investors regarding the safety of its Novum LVP device, which has been linked to serious malfunctions and risks to patient safety [1][3]. Summary by Sections Company Overview - Baxter International Inc. is a global company that develops, manufactures, and markets medical products used in hospitals and healthcare facilities [1]. Class Action Details - The class period for the lawsuit is from February 23, 2022, to July 30, 2025 [1]. - The lawsuit was filed on behalf of all investors who purchased or acquired Baxter's stock during this period [1]. Allegations Against Baxter - The complaint alleges that Baxter failed to disclose systemic defects in the Novum LVP device, which led to malfunctions such as underinfusion, overinfusion, and non-delivery of fluids, posing risks of serious injury or death to patients [3]. - Baxter was reportedly aware of multiple device malfunctions, injuries, and deaths but did not take adequate remedial measures [3]. - The company’s statements regarding the safety, efficacy, and sales prospects of the Novum LVPs were claimed to be materially false and misleading [3]. Impact on Stock Price - On July 31, 2025, Baxter announced a suspension of all new Novum LVP sales, leading to a 22.4% drop in stock price, closing at $21.76 [4]. Next Steps for Shareholders - Shareholders interested in participating in the class action must submit their papers by December 15, 2025, to serve as lead plaintiff [5]. - Shareholders can remain absent class members if they choose not to participate [5].

Core Viewpoint - A class action securities lawsuit has been filed against Baxter International, Inc. due to alleged securities fraud affecting investors between February 23, 2022, and July 30, 2025 [2][3]. Group 1: Lawsuit Details - The lawsuit claims that Baxter's product, the Novum LVP, had systemic defects leading to malfunctions such as underinfusion, overinfusion, and non-delivery of fluids, posing serious risks to patients [3]. - It is alleged that Baxter was aware of multiple device malfunctions, injuries, and deaths related to these defects [3]. - Baxter's attempts to address these issues through customer alerts were deemed inadequate, as design flaws persisted and continued to harm patients [3]. - The lawsuit suggests that there was an increased risk of customers being instructed to take existing Novum LVPs out of service and that Baxter would halt all new sales of these pumps [3]. - Baxter's statements regarding the safety, efficacy, product rollout, customer feedback, and sales prospects of the Novum LVPs were claimed to be materially false and misleading [3]. Group 2: Investor Information - Investors who suffered losses during the specified timeframe have until December 15, 2025, to request to be appointed as lead plaintiff [4]. - Participation in the lawsuit does not require any out-of-pocket costs or fees for class members [4]. Group 3: Legal Representation - Levi & Korsinsky, LLP has a strong track record in securities litigation, having secured hundreds of millions of dollars for shareholders over the past 20 years [5]. - The firm has been recognized in ISS Securities Class Action Services' Top 50 Report for seven consecutive years as one of the leading securities litigation firms in the United States [5].

Core Viewpoint - Baxter International, Inc. is facing a class action lawsuit due to allegations of issuing false and misleading statements regarding the safety and efficacy of its Novum LVP product, which reportedly has systemic defects leading to serious patient risks [3][4]. Group 1: Allegations and Issues - The complaint alleges that Baxter's Novum LVP product suffered from systemic defects causing malfunctions such as underinfusion, overinfusion, and complete non-delivery of fluids, exposing patients to serious injury or death [3]. - Baxter was reportedly notified of multiple device malfunctions, injuries, and deaths related to these defects, indicating a significant risk to patient safety [3]. - The company's attempts to address these defects through customer alerts were deemed inadequate, as design flaws persisted and continued to harm patients [3]. Group 2: Impact on Business Operations - Due to the defects, there is a heightened risk that customers may be instructed to take existing Novum LVPs out of service, and Baxter may need to pause all new sales of these pumps [3]. - Baxter's statements regarding the safety, efficacy, product rollout, customer feedback, and sales prospects of the Novum LVPs were found to be materially false and misleading, potentially impacting investor confidence and stock performance [3]. Group 3: Legal Proceedings and Shareholder Actions - Shareholders who purchased shares of Baxter during the class period from February 23, 2022, to July 30, 2025, are encouraged to register for the class action lawsuit, with a deadline for lead plaintiff appointment set for December 15, 2025 [4]. - Once registered, shareholders will be enrolled in a portfolio monitoring software to receive updates throughout the lifecycle of the case, indicating a structured approach to managing the legal proceedings [4].

Core Value Category - The biggest detractors in the Core Value category were Baxter International (BAX) and Philip Morris International (PM) [3]

Core Viewpoint - Baxter International, Inc. is facing a class action lawsuit due to allegations of issuing misleading statements regarding the safety and efficacy of its Novum LVP product, which reportedly has systemic defects leading to serious patient risks [1][2]. Summary by Sections Allegations - The lawsuit claims that Baxter's Novum LVP product had systemic defects causing malfunctions such as underinfusion, overinfusion, and non-delivery of fluids, posing risks of serious injury or death to patients [1]. - Baxter was allegedly aware of multiple device malfunctions, injuries, and deaths related to these defects [1]. - The company's attempts to address these issues through customer alerts were deemed inadequate, as design flaws persisted [1]. - There was an increased risk that customers would be instructed to take existing Novum LVPs out of service, and Baxter would halt all new sales of these pumps [1]. - Baxter's statements regarding the safety, efficacy, product rollout, customer feedback, and sales prospects of the Novum LVPs were claimed to be materially false and misleading [1]. Class Action Details - The class period for the lawsuit is from February 23, 2022, to July 30, 2025 [1]. - Shareholders who purchased shares during this period are encouraged to register for participation in the class action, with a deadline for lead plaintiff appointment set for December 15, 2025 [2]. Firm Background - The Gross Law Firm is a nationally recognized class action law firm focused on protecting investors' rights against deceit and fraud [3].

Core Viewpoint - Baxter International Inc. is facing a federal securities class action lawsuit due to allegations of making false statements regarding the safety and efficacy of its Novum LVP product, which has been linked to serious patient risks [5][6]. Group 1: Legal Action and Investor Information - Faruqi & Faruqi, LLP is investigating potential claims against Baxter and reminds investors of the December 15, 2025 deadline to seek the role of lead plaintiff in the class action lawsuit [2]. - Investors who suffered losses from Baxter's securities between February 23, 2022, and July 30, 2025, are encouraged to contact the law firm to discuss their legal rights [1][2]. Group 2: Allegations Against Baxter - The complaint alleges that Baxter and its executives violated federal securities laws by failing to disclose systemic defects in the Novum LVP, which caused malfunctions and posed risks of serious injury or death to patients [5]. - Baxter was reportedly aware of multiple device malfunctions, injuries, and deaths related to the Novum LVP but did not take adequate remedial measures [5]. - Following the announcement on July 31, 2025, regarding the voluntary pause of shipments and installations of the Novum LVP, Baxter's stock price dropped by 22.4%, closing at $21.76 [6][7].

Core Viewpoint - Rosen Law Firm is encouraging investors of Baxter International Inc. to secure legal counsel before the December 15, 2025 deadline for a securities class action related to the company's stock performance during the specified class period [2][3]. Group 1: Class Action Details - The class period for the lawsuit is from February 23, 2022, to July 30, 2025, and investors who purchased Baxter common stock during this time may be entitled to compensation without any out-of-pocket fees through a contingency fee arrangement [3][4]. - Investors wishing to serve as lead plaintiffs must file a motion with the court by December 15, 2025, to represent other class members in the litigation [4]. Group 2: Allegations Against Baxter - The lawsuit alleges that Baxter misled investors by failing to disclose systemic defects in the Novum IQ Large Volume Pump, which caused malfunctions that posed serious risks to patients [6]. - Specific issues cited include underinfusion, overinfusion, and complete non-delivery of fluids, along with inadequate remedial measures taken by Baxter despite being notified of multiple device malfunctions and associated injuries [6]. - The lawsuit claims that Baxter's statements regarding the safety, efficacy, and sales prospects of the Novum LVPs were materially false and misleading, leading to investor damages when the true details became public [6]. Group 3: Rosen Law Firm's Credentials - Rosen Law Firm emphasizes the importance of selecting qualified legal counsel with a successful track record in securities class actions, highlighting its own achievements in recovering hundreds of millions of dollars for investors [5]. - The firm has been recognized for its leadership in securities class action settlements, including being ranked No. 1 by ISS Securities Class Action Services in 2017 and securing over $438 million for investors in 2019 alone [5].

Core Viewpoint - Baxter International Inc. is facing a federal securities class action lawsuit due to allegations of making false and misleading statements regarding the safety and efficacy of its Novum LVP product, which has been linked to serious malfunctions and patient risks [3][4]. Summary by Sections Legal Investigation - Faruqi & Faruqi, LLP is investigating potential claims against Baxter International and has set a deadline of December 15, 2025, for investors to seek the role of lead plaintiff in the class action [1][5]. Allegations Against Baxter - The complaint alleges that Baxter and its executives violated federal securities laws by failing to disclose systemic defects in the Novum LVP, which led to malfunctions such as underinfusion and overinfusion, posing risks of serious injury or death to patients [3]. - Baxter was reportedly aware of multiple device malfunctions and injuries but did not take adequate remedial measures, leading to a heightened risk of customers removing the Novum LVPs from service [3]. Impact on Stock Price - Following the announcement on July 31, 2025, that Baxter would "voluntarily and temporarily pause shipments and planned installations" of the Novum LVP, the company's stock price fell by 22.4%, closing at $21.76 [4].

Core Viewpoint - A class action securities lawsuit has been filed against Baxter International, Inc. due to alleged securities fraud related to the company's product malfunctions and inadequate responses to safety concerns [1][2]. Group 1: Lawsuit Details - The lawsuit claims that Baxter's Novum LVP product had systemic defects leading to malfunctions such as underinfusion, overinfusion, and non-delivery of fluids, posing serious risks to patients [2]. - Baxter was reportedly aware of multiple device malfunctions, injuries, and fatalities linked to these defects [2]. - The company's attempts to address these issues through customer alerts were deemed insufficient, as design flaws persisted and continued to harm patients [2]. - There was an increased risk that customers would be advised to withdraw existing Novum LVPs from service, and Baxter might halt all new sales of these pumps [2]. - Baxter's statements regarding the safety, efficacy, product rollout, customer feedback, and sales prospects of the Novum LVPs were alleged to be materially false and misleading [2]. Group 2: Next Steps for Investors - Investors who experienced losses in Baxter International, Inc. during the specified period have until December 15, 2025, to request appointment as lead plaintiff [3]. - Participation in the lawsuit does not require serving as a lead plaintiff, and class members may be entitled to compensation without any out-of-pocket costs [3]. Group 3: Firm Background - Levi & Korsinsky, LLP has a history of securing significant settlements for shareholders and has been recognized as one of the top securities litigation firms in the United States for seven consecutive years [4].

Core Viewpoint - Baxter International, Inc. is facing a class action lawsuit due to allegations of issuing misleading statements regarding the safety and efficacy of its Novum LVP product, which reportedly has systemic defects leading to serious patient risks [1]. Summary by Sections Allegations - The lawsuit claims that Baxter's Novum LVP product suffered from systemic defects causing malfunctions such as underinfusion, overinfusion, and non-delivery of fluids, posing risks of serious injury or death to patients [1]. - Baxter was allegedly aware of multiple device malfunctions, injuries, and deaths related to these defects [1]. - The company's attempts to address these issues through customer alerts were deemed inadequate, as design flaws persisted [1]. - There was an increased risk that customers would be instructed to take existing Novum LVPs out of service, and Baxter would halt all new sales of these pumps [1]. - Baxter's statements regarding the safety, efficacy, product rollout, customer feedback, and sales prospects of the Novum LVPs were claimed to be materially false and misleading [1]. Class Action Details - The class period for the lawsuit is from February 23, 2022, to July 30, 2025 [1]. - Shareholders who purchased shares during this period are encouraged to register for participation in the class action, with a deadline for lead plaintiff appointment set for December 15, 2025 [2]. - Registered shareholders will receive updates through a portfolio monitoring software throughout the case lifecycle [2]. Law Firm Information - The Gross Law Firm is a nationally recognized class action law firm focused on protecting investors' rights against deceit and fraud [3]. - The firm aims to ensure companies adhere to responsible business practices and seeks recovery for investors who suffered losses due to misleading statements or omissions [3].